Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy
- 13 March 2016
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 30 (5) , 787-796
Abstract
Clinical series suggest favorable outcomes of HIV-associated Hodgkin lymphoma, in conflict with population-based statistics. Our objective was to investigate the proportion of Americans who received curative chemotherapy for this disease, and compare their survival with HIV-negative cases using population data. We selected cases of HIV-associated Hodgkin lymphoma diagnosed in 2004-2012 from the National Cancer Data Base. Factors associated with receipt of chemotherapy were analyzed by logistic regression. Overall survival was compared in proportional hazard models adjusting for available confounding factors. Among 2090 HIV-positive patients, 81% received chemotherapy, but 16% received no treatment. Advanced age, male sex, nonwhite race, poor socioeconomic status, and undetermined histologic subtype were associated with higher risk of nontreatment. In 2012, 49% of HIV-positive patients were black, and 15% were Hispanic. Unadjusted 5-year overall survival was significantly lower for HIV-positive (66%) than for HIV-negative (80%) populations. However, among patients who received chemotherapy, HIV-positive status was not significantly associated with higher mortality in classical histologic subtypes, including nodular sclerosis (hazard ratio, HR, 1.08; 95% confidence interval, CI, 0.88-1.33) and mixed cellularity (HR, 1.06; 95% CI, 0.80-1.40). In contrast, prognosis remained significantly worse for cases with undetermined histology (HR, 1.56; 95% CI, 1.31-1.85), suggesting a more aggressive biology or other high-risk characteristics in this subgroup. Worse survival statistics for HIV-associated Hodgkin lymphoma are driven by lower rates of chemotherapy administration. The disparity in treatment delivery needs attention because a majority of HIV-positive Americans with Hodgkin lymphoma are now black or Hispanic, and this proportion is increasing.Keywords
This publication has 36 references indexed in Scilit:
- Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy EraJNCI: Journal of the National Cancer Institute, 2013
- Clinical Characteristics, Incidence, and Risk Factors of HIV-Related Hodgkin Lymphoma in the Era of Combination Antiretroviral TherapyAIDS Patient Care and STDs, 2013
- Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphomaAIDS, 2010
- Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort studyThe Lancet Oncology, 2009
- Comparison of Commission on Cancer–Approved and –Nonapproved Hospitals in the United States: Implications for Studies That Use the National Cancer Data BaseJournal of Clinical Oncology, 2009
- Approaches for estimating prevalence ratiosOccupational and Environmental Medicine, 2008
- The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United StatesAnnals of Surgical Oncology, 2008
- Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDSBlood, 2006
- Incidence of Non–AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus–Infected PatientsJournal of Clinical Oncology, 2003
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994